Alternative strategies

Carmignac Portfolio Merger Arbitrage Plus

Share Class

LU2585801173

Carmignac Portfolio Merger Arbitrage Plus fund performance

Performance Overview

Data as of:  5 Feb 2025.

Calendar Year Performance (as %)

Calendar Year Performance (as %)

Data as of:  31 Dec 2024.
Carmignac Portfolio Merger Arbitrage Plus - I GBP Hdg Acc
Carmignac Portfolio Merger Arbitrage Plus I GBP Hdg Acc+4.6 %---
Category Average----
Ranking (quartile)----
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). Morningstar Rating™ :  © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Source: Carmignac at 31/12/2024.

Statistics (%)

These measures are used to assess a Fund's risk-adjusted performance. A well-performing Fund should ideally have a solid return (measured by the Sharpe ratio and alpha) relative to its risk (measured by volatility), while being well aligned with market expectations (measured by beta relative to the reference indicator).

Volatility

Data as of:  31 Dec 2024.
Fund+1.8 %-+1.9 %

Calculation : Weekly basis

Source: Carmignac at 31 Dec 2024.

Comments from the Investment Team

Read the Investment team's analysis below.

Carmignac Portfolio Merger Arbitrage Plus Monthly comments

Data as of:  31 Dec 2024.
The Investment team

Market Environment

  • A rather quiet end to the year for the Merger Arbitrage strategy, with no major events in December.

  • The HFRX Merger Arbitrage index remained virtually stable over the month, ending the year down -1.84%.

  • It is worth noting the strategy's good decorrelation during December in relation to the equity market, with the S&P 500 down -2.4%, and the credit market, with the US IG index down -2.6%.

  • There was some good news on the antitrust front: Catalent finally closed before the end of the year, rumors of the DoJ blocking Juniper have gradually faded, and Chinese press reports seem to indicate that the approval process for the acquisition of Shinko Electric Industries is well underway.

  • After several weeks of waiting, a US federal judge finally decided to block the Albertsons/Kroger deal. Anticipated by the markets, this decision had no significant impact on Albertsons' share price.

  • Measured in terms of the number of transactions, M&A activity remained buoyant in December, with 34 deals announced worldwide, up 21% versus the previous month.

  • Of particular note was the announcement of only 1 deal in excess of $10 billion: the merger in the US advertising sector between Interpublic and Omnicom.

  • As in the previous month, financial players accounted for more than a third of announced deals.

Performance Commentary

  • The fund posted a positive performance for the month.

  • Main positive contributors to performance were: Shinko Electric Industries Catalent, and Hess.

  • Main negative contributors to performance were: Enstar Group, Albertsons and Arcadium Lithium.

Outlook and Investment Strategy

  • The fund's investment rate 94%, down on the previous month.

  • With 38 positions in the portfolio, diversification remains satisfactory.

  • 2024 was a very complicated year for Merger Arbitrage: strong antitrust pressure, particularly in the US, with some deals blocked (Capri, Albertsons) and others under increased scrutiny (Hess, Pioneer Natural Resources, Catalent or Juniper).

  • We therefore witnessed a recovery in M&A activity that was not as strong as expected, due to increased scrutiny by the competition authorities, and highly volatile transactions (DS Smith, United States Steel, China Traditional Chinese Medicine) that led to the unwinding and closure of several Merger Arbitrage portfolios within the largest investment platforms.

  • The outlook for 2025 is much brighter, thanks to a more favorable antitrust environment for M&A activity worldwide.

  • The change of administration in the US following Trump's election, the publication of the Draghi report in Europe recommending the emergence of national champions to face global competition, the regulator in the UK pushed by the political class to prioritize economic activity and a Japanese market that continues to open up to foreign capital.

  • Lower interest rates are also likely to drive M&A activity in the quarters ahead.

Related articles

Alternative Strategy18 March 2024English

Our Merger Arbitrage strategy wins ‘Best new launch’ award

1 minute(s) read
Find out more
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.